Vladislava T Djurasinović1,2, Biljana S Mihaljević3,4, Sandra B Šipetić Grujičić5, Svetlana D Ignjatović6, Goran Trajković7, Milena R Todorović-Balint3,4, Darko A Antić3,4, Jelena S Bila3,4, Boško M Andjelić3,4, Jelena J Jeličić3, Vojin M Vuković3, Aleksandra M Nikolic5, Stanislaw Klek8. 1. Clinic for Hematology, Clinical Center of Serbia, Koste Todorovica 2, Belgrade, Serbia. vladislavadj@yahoo.co.uk. 2. Faculty of Medicine, University of Belgrade, Dr Subotica 8, Belgrade, Serbia. vladislavadj@yahoo.co.uk. 3. Clinic for Hematology, Clinical Center of Serbia, Koste Todorovica 2, Belgrade, Serbia. 4. Faculty of Medicine, University of Belgrade, Dr Subotica 8, Belgrade, Serbia. 5. Faculty of Medicine, Institute of Epidemiology, University of Belgrade, Višegradska 26a, Belgrade, Serbia. 6. Pharmaceutical Faculty, University of Belgrade, Vojvode Stepe 450, Belgrade, Serbia. 7. Faculty of Medicine, Department of Medical Statistics and Informatics, University of Belgrade, Dr Subotica 5, Belgrade, Serbia. 8. General Surgery Unit, Stanley Dudrick's Memorial Hospital, 15 Tyniecka Street, 32-050, Skawina, Poland.
Abstract
INTRODUCTION: Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. METHODOLOGY: Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. RESULTS: There were 37 (27.8%) patients with the severe 25(OH)D deficiency ≤ 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D < 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). CONCLUSION: The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D < 19.6 nmol/l had a significantly shorter PFS.
INTRODUCTION:Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. METHODOLOGY: Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. RESULTS: There were 37 (27.8%) patients with the severe 25(OH)D deficiency ≤ 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D < 19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). CONCLUSION: The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D < 19.6 nmol/l had a significantly shorter PFS.
Authors: Jennifer L Kelly; Gilles Salles; Bryan Goldman; Richard I Fisher; Pauline Brice; Oliver Press; Olivier Casasnovas; David G Maloney; Pierre Soubeyran; Lisa Rimsza; Corinne Haioun; Luc Xerri; Michael LeBlanc; Hervé Tilly; Jonathan W Friedberg Journal: J Clin Oncol Date: 2015-03-30 Impact factor: 44.544
Authors: Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl Journal: J Clin Oncol Date: 2007-01-22 Impact factor: 44.544
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Heike A Bischoff-Ferrari; Edward Giovannucci; Walter C Willett; Thomas Dietrich; Bess Dawson-Hughes Journal: Am J Clin Nutr Date: 2006-07 Impact factor: 7.045
Authors: J Polesel; R Talamini; M Montella; M Parpinel; L Dal Maso; A Crispo; M Crovatto; M Spina; C La Vecchia; S Franceschi Journal: Ann Oncol Date: 2006-04 Impact factor: 32.976
Authors: Federico Bozzetti; Luigi Mariani; Salvatore Lo Vullo; Maria Luisa Amerio; Roberto Biffi; Giovanni Caccialanza; Giorgio Capuano; Giovanni Capuano; Isabel Correja; Luca Cozzaglio; Angelo Di Leo; Leonardo Di Cosmo; Concetta Finocchiaro; Cecilia Gavazzi; Antonello Giannoni; Patrizia Magnanini; Giovanni Mantovani; Manuela Pellegrini; Lidia Rovera; Giancarlo Sandri; Marco Tinivella; Enrico Vigevani Journal: Support Care Cancer Date: 2012-08 Impact factor: 3.603
Authors: Martin Fortin; Catherine Hudon; Marie-France Dubois; José Almirall; Lise Lapointe; Hassan Soubhi Journal: Health Qual Life Outcomes Date: 2005-11-23 Impact factor: 3.186